Clinical trial
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
NCT00301990 · Jonsson Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00301990 |
|---|---|
| Title | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer |
| Official title | A Phase II Study of Bevacizumab and Aldesleukin in Patients With Metastatic Renal Cell Carcinoma (RCC): A Cytokine Working Group (CWG) Study |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological |
| Interventions | aldesleukin, bevacizumab |
| Enrollment | 65 |
| Start date | Sep 1, 2005 |
| First posted | Mar 13, 2006 |
| Last update posted | Jan 10, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: